Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
JCO Precision Oncology|March 30, 2026
Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA SubstudyYuqing Duan, Tadayoshi Hashimoto, Taro Shibuki, et al.
Oncotarget|September 17, 2016
Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancerHannah Nip, Altaf A Dar, Sharanjot Saini, et al.
Molecular Cancer Research : MCR|March 1, 2017
Versican Promotes Tumor Progression, Metastasis and Predicts Poor Prognosis in Renal CarcinomaYozo Mitsui, Hiroaki Shiina, Taku Kato, et al.
International Journal of Clinical Oncology|March 6, 2026
Clinical development of molecular residual disease (MRD) and multi-cancer early detection (MCED) using liquid biopsy multiomics with artificial intelligence (AI)Taro Shibuki, Riu Yamashita, Tadayoshi Hashimoto, et al.
JAMA Network Open|December 5, 2022
Concordance Between Recommendations From Multidisciplinary Molecular Tumor Boards and Central Consensus for Cancer Treatment in JapanYoichi Naito, Kuniko Sunami, Hidenori Kage, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2024
Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal CancerNaoko Iida, Mitsuho Imai, Wataru Okamoto, et al.
International Journal of Clinical Oncology|May 23, 2026
SCRUM-Japan MONSTAR3 hematology cohort: a nationwide multi-omics integrated platform for next-generation precision medicine in hematologic malignanciesKensuke Matsuda, Junichiro Yuda, Ryo Yoshimaru, et al.
Journal of Gastroenterology|May 25, 2026
Clinico-molecular characteristics and enhanced efficacy of immune checkpoint inhibitors in TP53-mutated advanced biliary tract cancerTaro Shibuki, Celine Hoyek, Ryne Ramaker, et al.
Cancer Science|June 2, 2025
Landscape Analysis of CLDN18 Expression and Isoform Distribution in Solid Tumors: Insights From MONSTAR-SCREEN-2 StudyTadayoshi Hashimoto, Naoko Iida, Yoshiaki Nakamura, et al.
International Journal of Clinical Oncology|July 27, 2026
AI-integrated multi-omics platform to revolutionize anti-metastatic therapy development through circulating tumor cell profiling: SCRUM-MONSTAR-CTCTadayoshi Hashimoto, Taro Shibuki, Takao Fujisawa, et al.
Pageof 4